The ICE3 trial is designed to evaluate the safety and efficacy of breast cryoablation, enabling women older than 60 years with low-risk early-stage breast cancers to benefit from a nonsurgical treatment and to avoid the associated surgical risks.
The ICE3 trial is a prospective, multi-center, single-arm, non-randomized trial including women age 60 years or older with unifocal, ultrasound-visible invasive ductal carcinoma size 1.5 cm or smaller and classified as low to intermediate grade, hormone receptor (HR)-positive, and human epidermal growth factor receptor 2 (HER2)-negative. Ipsilateral breast tumor recurrence (IBTR) at 5 years was the primary outcome. A 3-year interim analysis of IBTR was performed, and the IBTR probability was estimated using the Kaplan-Meier method.
Full eligibility for the study was met by 194 patients, who received successful cryoablation per protocol. The mean age was 75 years (range, 55–94 years). The mean tumor length was 8.1 mm (range, 8–14.9 mm), and the mean tumor width was 7.4 mm (range, 2.8–14 mm). During a mean follow-up period of 34.83 months, the IBTR rate was 2.06% (4/194 patients). Device-related adverse events were reported as mild in 18.4% and moderate in 2.4% of the patients. No severe device-related adverse events were reported. More than 95% of the patients and 98% of the physicians reported satisfaction with the cosmetic results at the clinical follow-up evaluation.
Breast cryoablation presents a promising alternative to surgery while offering the benefits of a minimally invasive procedure with minimal risks. Further study within a clinical trial or registry is needed to confirm cryoablation as a viable alternative to surgical excision for appropriately selected low-risk patients.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
American Cancer Society: Facts and figures for 2021. Retrieved May 15, 2021, at https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf.
Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41. https://doi.org/10.1056/NEJMoa022152.
Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):971–77. https://doi.org/10.1056/NEJMoa040587.
The Society of Surgical Oncology Encourages Doctors, Patients to Question Specific Commonly-Used Tests and Treatments as Part of Choosing Wisely Campaign. Retrieved 22 April 2018 at http://www.surgonc.org/news-publications/for-the-press/2016/07/12/the-society-of-surgical-oncology-encourages-doctors-patients-to-question-specific-commonly-used-tests-and-treatments-as-part-of-choosing-wisely-campaign.
Permissions Distress Tool. NCCN. Retrieved 13 May 2021 at https://www.nccn.org/guidelines/submissionslicensing-and-permissions/permissions-distress-tool.
U.S. Department of Health and Human Services (28 May 2009). Common Criteria for AdverseEvents(CTCAE)Version4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf.
Gage AA. History of cryosurgery. Semin Surg Oncol. 1998;14(2):99–109. https://doi.org/10.1002/(SICI)1098-2388(199803)14:299::AID-SSU23.0.CO;2-1.
Inoue M, Nakatsuka S, Yashiro H, et al. Percutaneous cryoablation of lung tumors: feasibility and safety. J Vasc Intervent Radiol. 2012;23(3):295–302. https://doi.org/10.1016/j.jvir.2011.11.019.
Miki K, Shimomura T, Yamada H, et al. Percutaneous cryoablation of renal cell carcinoma guided by horizontal open magnetic resonance imaging. Int J Urol. 2006;13(7):880–4. https://doi.org/10.1111/j.1442-2042.2006.01432.x.
Ei S, Hibi T, Tanabe M, et al. Cryoablation provides superior local control of primary hepatocellular carcinomas of >2 cm compared with radiofrequency ablation and microwave coagulation therapy: an underestimated tool in the toolbox. Ann Surg Oncol. 2015;22(4):1294–300. https://doi.org/10.1245/s10434-014-4114-7.
Igarashi K, Yamamoto N, Shirai T, et al. The long-term outcome following the use of frozen autograft treated with liquid nitrogen in the management of bone and soft-tissue sarcomas. Bone Jt J. 2014;96-B(4):555–61. https://doi.org/10.1302/0301-620X.96B4.32629.
Baust JG, Bischof JC, Jiang-Hughes S, et al. Re-purposing cryoablation: a combinatorial “therapy” for the destruction of tissue. Prostate Cancer Prostatic Dis. 2015;18(2):87–95. https://doi.org/10.1038/pcan.2014.54.
Baust JG, Gage AA, Bjerklund Johansen TE, Baust JM. Mechanisms of cryoablation: clinical consequences on malignant tumors. Cryobiology. 2014;68(1):1–11. https://doi.org/10.1016/j.cryobiol.2013.11.001.
Sabel MS, Nehs MA, Su G, Lowler KP, Ferrara JLM, Chang AE. Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat. 2005;90(1):97–104. https://doi.org/10.1007/s10549-004-3289-1.
Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14(3):199–208. https://doi.org/10.1038/nrc3672.
Gage AA, Baust JG. Cryosurgery for tumors: a clinical overview. Tech Cancer Res Treat. 2004;3(2):187–99. https://doi.org/10.1177/153303460400300212.
Sabel MS, Su G, Griffith KA, Chang AE. Rate of freeze alters the immunologic response after cryoablation of breast cancer. Ann Surg Oncol. 2010;17(4):1187–93. https://doi.org/10.1245/s10434-009-0846-1.
Tatsutani K, Rubinsky B, Onik G, Dahiya R. Effect of thermal variables on frozen human primary prostatic adenocarcinoma cells. Urology. 1996;48(3):441–7. https://doi.org/10.1016/S0090-4295(96)00199-9.
Whitworth PW, Rewcastle JC. Cryoablation and cryolocalization in the management of breast disease. J Surg Oncol. 2005;90(1):1–9. https://doi.org/10.1002/jso.20201.
Kaufman CS, Bachman B, Littrup PJ, et al. Cryoablation treatment of benign breast lesions with 12-month follow-up. Am J Surg. 2004;188(4):340–8. https://doi.org/10.1016/j.amjsurg.2004.06.025.
Kaufman CS, Rewcastle JC. Cryosurgery for breast cancer. Tech Cancer Res Treat. 2004;3(2):165–75. https://doi.org/10.1177/153303460400300209.
Golatta M, Harcos A, Pavlista D, et al. Ultrasound-guided cryoablation of breast fibroadenoma: a pilot trial. Arch Gynecol Obstet. 2015;291:1355–60.
Staren ED, Sabel MS, Gianakakis LM, et al. Cryosurgery of breast cancer. Arch Surg. 1997;132(1):28–33. https://doi.org/10.1001/archsurg.1997.01430250030005.
Sabel MS, Kaufman CS, Whitworth P, et al. Cryoablation of early-stage breast cancer: work-in-progress report of a multi-institutional trial. Ann Surg Oncol. 2004;11(5):542–9. https://doi.org/10.1245/ASO.2004.08.003.
Manenti G, Scarano AL, Pistolese CA, et al. Subclinical breast cancer: minimally invasive approaches: our experience with percutaneous radiofrequency ablation vs cryotherapy. Breast Care. 2013;8(5):356–60. https://doi.org/10.1159/000355707.
Manenti G, Perretta T, Gaspari E, et al. Percutaneous local ablation of unifocal subclinical breast cancer: clinical experience and preliminary results of cryotherapy. Eur Radiol. 2011;21(11):2344–53. https://doi.org/10.1007/s00330-011-2179-2.
Simmons RM, Ballman K, Cox C, et al. A phase II trial exploring the success of cryoablation therapy in the treatment of invasive breast carcinoma: results from ACOSOG (Alliance) Z1072. Ann Surg Oncol. 2016;23(8):2438–45. https://doi.org/10.1245/s10434-016-5275-3.
Littrup PJ, Jallad B, Chandiwala-Mody P, D’Agostini M, Adam BA, Bouwman D. Cryotherapy for breast cancer: a feasibility study without excision. J Vasc Intervent Radiol. 2009;20(10):1329–41. https://doi.org/10.1016/j.jvir.2009.06.029.
Adachi T, Machida Y, Fukuma E, Tateishi U. Fluorodeoxyglucose positron emission tomography/computed tomography findings after percutaneous cryoablation of early breast cancer. Cancer Imaging. 2020;20(1):49. https://doi.org/10.1186/s40644-020-00325-y.
Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31:2382–7. https://doi.org/10.1200/JCO.2012.45.2615.
Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM. PRIME II Investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16:266–73. https://doi.org/10.1016/S1470-2045(14)71221-5.
Habrawi Z, Melkus MW, Khan S, et al. Cryoablation: a promising nonoperative therapy for low-risk breast cancer. Am J Surg. 2021;221(1):127–133. https://doi.org/10.1016/j.amjsurg.2020.07.028.
van de Voort E, Struik GM, Birnie E, Moelker A, Verhoef C, Klem T. Thermal ablation as an alternative for surgical resection of small (≤2 cm) breast cancers: a meta-analysis. Clin Breast Cancer. 2021. https://doi.org/10.1016/j.clbc.2021.03.004.
Funding for this trial was provided by IceCure Medical Ltd., Caesarea, Israel. Ravit Attali, RN, MPH is the Clinical Director of IceCure Medical Ltd. NIH Trial Registration No: https://clinicaltrials.gov/ct2/show/NCT02200705.
Andrew Kenler was the medical Director of Icecure for approximately five years and during the time period of this study and was paid for my time as medical Director. That relationship ended approximately one year ago; Kenneth Tomkovich: Stipend received for data entry for patients enrolled in trial to CentraState medical center by IceCure medical. Probes and cryoablation unit provided by IceCure medical to conduct the trial. I received no personal funds for conducting the trial or for the preparation of this manuscript. Neither I nor my medical institution have any relevant conflict of interest in conducting this research; Richard Fine: West Cancer Center & Research Institute (Author's institution) received financial support for conducting the clinical trial. Served on the original scientific advisory board that participated in the Ice3 trial protocol design. Expenses were reimbursed for travel to Chicago, Il in 2014; Margaret Chen-Seetoo: Novian Health—research grant; Theraclion—research grant; Agendia—research grant; PreludeDx—research grant; Susan Seedman profited $280 from prior purchase and sale of publicly traded stock.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Fine, R.E., Gilmore, R.C., Dietz, J.R. et al. Cryoablation Without Excision for Low-Risk Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial. Ann Surg Oncol 28, 5525–5534 (2021). https://doi.org/10.1245/s10434-021-10501-4